Table 1

Increasing IgG titers to Lassa virus antigens through the vaccination schedule

Immunogen


Z+GPC VLP

Z+GPC+NP VLP

ELISA Ag

naive

pre- 1st

boost

pre- 2nd boost

term.

naive

pre- 1st

boost

pre-

2nd boost

term.

p value

VLP

18 ±

17

556 ±

975

2667 ±

1058

12800 ±

14311

50 ±

0

9920 ±

4637

19520 ±

16963

32000 ±

20239

0.026

sGP1

< 10

88 ±

69

200 ±

254

444 ±

384 **

< 10

1520 ±

1159

2480 ±

1159

6800 ±

5215

0.004

GPCΔTM

< 10

95 ±

72

215 ±

217

700 ±

992 *

< 10

2960 ±

3657

3440 ±

3478

10400 ±

15179

0.092

NP

< 10

560 ±

310

1220 ±

1060

2000 ±

1265


Endpoint ELISA titers for each timed point are mean ± SD, N = 10, except for starred entries, where * N = 9 and ** N = 8. The p value for terminal endpoint IgG titers generated against relevant LASV antigens between the two VLP formats is shown. Samples were collected on days 21 (pre-1st boost), 42 (pre-2nd boost) and 63 (term.) for titer analysis.

Branco et al. Virology Journal 2010 7:279   doi:10.1186/1743-422X-7-279

Open Data